According to BioCryst Pharmaceuticals 's latest financial reports and stock price the company's current Operating Margin is -30.08%. At the end of 2023 the company had an Operating Margin of -68.26%.
Year | Operating Margin | Change |
---|---|---|
2023 | -68.26% | -24.35% |
2022 | -90.24% | -21.99% |
2021 | -115.68% | -88.73% |
2020 | -1,026.35% | 360.27% |
2019 | -222.99% | -54.52% |
2018 | -490.25% | 87.7% |
2017 | -261.18% | 24.82% |
2016 | -209.25% | 134.73% |
2015 | -89.15% | -73.16% |
2014 | -332.08% | 91.15% |
2013 | -173.72% | 16.88% |
2012 | -148.64% | -48.73% |
2011 | -289.91% | 434.23% |
2010 | -54.27% | 194.66% |
2009 | -18.42% | -61.65% |
2008 | -48.03% | 5.99% |
2007 | -45.31% | -94.01% |
2006 | -756.28% | -95.77% |
2005 | -17,895.15% | 177.17% |
2004 | -6,456.46% | 208.3% |
2003 | -2,094.18% | 98.69% |
2002 | -1,053.98% | 2258.83% |
2001 | -44.68% |
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.